Dyne Therapeutics (NASDAQ:DYN) Given New $30.00 Price Target at Royal Bank Of Canada

Dyne Therapeutics (NASDAQ:DYN) had its price target dropped by equities researchers at Royal Bank Of Canada from $35.00 to $30.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target would suggest a potential upside of 47.71% from the stock’s current price.

A number of other analysts have also recently weighed in on DYN. Cantor Fitzgerald began coverage on shares of Dyne Therapeutics in a report on Thursday, July 23rd. They set an “overweight” rating on the stock. Sanford C. Bernstein lifted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Evercore set a $33.00 price target on Dyne Therapeutics in a research report on Friday, May 15th. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday, August 17th. Finally, TD Cowen assumed coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.92.

Dyne Therapeutics Trading Down 16.4%

Shares of NASDAQ DYN opened at $20.31 on Wednesday. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. The stock’s 50 day moving average price is $24.82 and its two-hundred day moving average price is $20.49. Dyne Therapeutics has a 52-week low of $11.92 and a 52-week high of $27.31. The stock has a market capitalization of $3.79 billion, a P/E ratio of -6.10 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, analysts anticipate that Dyne Therapeutics will post -3.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO John Cox sold 5,658 shares of Dyne Therapeutics stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total transaction of $106,823.04. Following the sale, the chief executive officer directly owned 357,507 shares in the company, valued at $6,749,732.16. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason Rhodes sold 2,160,516 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares in the company, valued at approximately $10,723,650. The trade was a 83.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,150,974 shares of company stock worth $99,697,629 over the last three months. Corporate insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Hilton Head Capital Partners LLC bought a new stake in Dyne Therapeutics during the first quarter worth approximately $26,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at $51,000. Allworth Financial LP acquired a new stake in Dyne Therapeutics during the 2nd quarter worth about $62,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Dyne Therapeutics in the fourth quarter worth about $84,000. Finally, Steward Partners Investment Advisory LLC lifted its position in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

More Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne will present six- and 12-month data from the Phase 1/2 ACHIEVE trial at the World Muscle Society and AANEM meetings beginning September 29-30. The presentation will include comparisons with a matched natural-history cohort and updated safety results, providing a near-term potential catalyst. Dyne ACHIEVE trial data announcement
• Positive Sentiment: The ACHIEVE registrational expansion cohort is fully enrolled, with topline results expected in the first quarter of 2027. Z-basivarsen also carries FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, which could support an expedited development path. ACHIEVE trial data summary
• Neutral Sentiment: Options activity was unusually high, with traders purchasing about 20,532 call options versus average volume of roughly 464. The activity may indicate speculative expectations for a rebound or positive clinical news, but it does not establish a fundamental change in Dyne’s outlook.
• Neutral Sentiment: A Seeking Alpha analysis continued to rate DYN a buy, arguing that Dyne’s clinical program may remain differentiated despite negative developments elsewhere in the DM1 field. This represents a more constructive view than the latest brokerage downgrade.
• Negative Sentiment: JPMorgan downgraded Dyne Therapeutics (DYN) from “neutral” to “underweight” and set a $10 price target, implying substantial downside from the referenced market level. The downgrade is likely the most direct source of selling pressure today.
• Negative Sentiment: Shares fell sharply after a competing DM1 therapy failed in a Phase 3 trial. Investors appear concerned that the setback could expose challenges for the DM1 drug class or raise the bar for Dyne’s upcoming data, even though the company’s own results have not yet been reported. Report on rival DM1 trial failure
• Negative Sentiment: Several executives reported stock sales, including CEO John Cox. The filings state that the transactions were made to cover tax withholding on vested equity awards and were small relative to the insiders’ remaining holdings, reducing their significance but adding to cautious sentiment.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.